Soonmyung Hwang

Soonmyung Hwang

Auto-generated profile, based on publicly available information

Soonmyung Hwang

Icahn School of Medicine at Mount Sinai, New York, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2021 in Cell Chemical Biology
Verified
Journal Article
Closed access
EAEfrat Abramson
Efrat Abramson
CHClayton Hardman
Clayton Hardman
ASAkira J. Shimizu
Akira J. Shimizu
SHSoonmyung Hwang
Soonmyung Hwang
LHLynda D. Hester
Lynda D. Hester
MKMichael D. Kornberg
Michael D. Kornberg

8 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
PGPayam Gharibani
Payam Gharibani
EAEfrat Abramson
Efrat Abramson
SSShruthi Shanmukha
Shruthi Shanmukha
MSMatthew D. Smith
Matthew D. Smith
WGWesley H. Godfrey
Wesley H. Godfrey
PKPaul M. Kim
Paul M. Kim
In multiple sclerosis (MS), microglia and macrophages within the central nervous system (CNS) play an important role in determining the balance among demyelination, neurodegeneration, and myelin repair. Phagocytic and regenerative functions of these CNS innate immune cells support remyelination, whereas chronic and maladaptive inflammatory activation promotes lesion expansion and disability, particularly in the progressive forms of MS. No currently approved drugs convincingly target microglia and macrophages within the CNS, contributing to the lack of therapies aimed at promoting remyelination and slowing disease progression for individuals with MS. Here, we found that the protein kinase C (PKC)–modulating drug bryostatin-1 (bryo-1), a CNS-penetrant compound with an established human safety profile, shifts the transcriptional programs of microglia and CNS-associated macrophages from a proinflammatory phenotype to a regenerative phenotype in vitro and in vivo. Treatment of microglia with bryo-1 stimulated scavenger pathways, phagocytosis, and secretion of factors that prevented the activation of neuroinflammatory reactive astrocytes while also promoting neuroaxonal health and oligodendrocyte differentiation. In line with these findings, systemic treatment of mice with bryo-1 augmented remyelination after a focal demyelinating injury. Our results demonstrate the potential of bryo-1 and possibly a wider class of PKC modulators as myelin-regenerative and supportive agents in MS and other neurologic diseases.

30 April 2025 in Telemedicine and e-Health
Verified
Journal Article
Closed access
SHSoonmyung Hwang
Soonmyung Hwang
PAParul Agarwal
Parul Agarwal
MDMark Dakov
Mark Dakov
MDMargaret H. Downes
Margaret H. Downes
BKBenjamin R. Kummer
Benjamin R. Kummer
Introduction: : Interprofessional electronic consultations (eConsults) can reduce health care utilization and improve access to specialty care. However, health care utilization and access impacts of eConsults for headache disorders remain incompletely characterized. Methods: : We conducted a retrospective, 1:3-matched cohort study comparing patients referred for in-person headache evaluations to patients who had a headache-related eConsult. The cohorts were propensity score-matched by age, sex, race, preferred language, provider specialty, insurance status, and medical comorbidities. Our primary outcome was the presence of one or more headache-related ambulatory encounters in the 12 months following the index referral date. We used univariable and conditional logistic regression models to ascertain the associations between referral type and outcome. Results: : We identified 74 and 222 patients with eConsult and in-person referrals, respectively. Over the follow-up period, the proportion of patients with the primary outcome was significantly greater in the eConsult cohort than the in-person cohort (46.0% vs. 43.2%, p < 0.0001). A greater proportion of the in-person cohort had one or more ambulatory headache encounters in the 12 months preceding their referral than the eConsult cohort (10.8% vs. 5.4%, p < 0.0001). In the adjusted analysis, eConsult usage was not associated with significantly increased odds of the primary outcome (adjusted odds ratio [aOR] 1.1, 95% confidence interval [CI] 0.6–2.0, p = 0.71), although patients with one or more ambulatory neurology encounters in the preceding 12 months had significantly increased odds of the primary outcome (aOR 3.1, 95% CI 1.2–7.9, p = 0.015). Conclusion: : Compared to in-person referrals, eConsult use for headache was not associated with significantly increased odds of having subsequent ambulatory headache-related encounters.

16 July 2024 in Telemedicine and e-Health
Verified
Journal Article
Closed access
BKBenjamin Kummer
Benjamin Kummer
SHSoonmyung Hwang
Soonmyung Hwang
PAParul Agarwal
Parul Agarwal
Introduction: Interprofessional consultations (“eConsults”), which facilitate asynchronous specialist consultations, remain understudied in neurological disorders. We aimed to describe the patient population receiving eConsult services for neurological disorders nationwide and to conduct a comparative analysis between rural and urban patients within this eConsult cohort. Methods: We analyzed a dataset of U.S. outpatient claims from employer-sponsored commercial and Medicare plans. Using standardized mean differences, we compared clinical and sociodemographic patient characteristics between urban and rural patients within the eConsult group. Results: We identified 1,374 patients who had an eConsult order for a neurological disorder. Overall eConsult volume increased by 548.5% between 2019 and 2021. A majority of the cohort were aged 65 years or older (23.7%), had an eConsult order in 2021 (52.4%), and live in an urban area (90.4%). The primary diagnosis for our cohort was likely to be a sleep-wake disorder (21.9%), cerebrovascular disease (14.3%), neurological sign or symptom (14.2%), or headache (13.7%). In the secondary analysis, rural eConsult patients exhibited higher rates of primary diagnoses for traumatic brain injury, neuroophthalmic disorders, or neuropathy than their urban counterparts. Discussion: In this national sample of commercially insured patients, the utilization of eConsults for neurological conditions increased nationwide since 2019, especially for patients living in rural areas.

23 September 2025 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
JNJaan K Nandwani
Jaan K Nandwani
SHSoonmyung A Hwang
Soonmyung A Hwang
LBLeah Blank
Leah Blank
BKBenjamin R Kummer
Benjamin R Kummer
PAParul Agarwal
Parul Agarwal

10 January 2025 in Telemedicine and e-Health
Verified
Journal Article
Closed access
SHSoonmyung Hwang
Soonmyung Hwang
RBRebecca Baron
Rebecca Baron
VSVrinda Saxena
Vrinda Saxena
PAParul Agarwal
Parul Agarwal
BKBenjamin Kummer
Benjamin Kummer
Introduction: : The use of remote patient monitoring (RPM) services for neurological disorders remains understudied, particularly in the context of newer billing codes introduced before the COVID-19 pandemic. Methods: : This retrospective cohort study utilized data from commercial and Medicare employer-sponsored administrative claims between January 1, 2019, to December 31, 2021. The study population included all patients with at least one qualifying RPM-related Current Procedural Terminology (CPT) code for a neurological disorder, separated into first-generation (CPT 99091) codes and second-generation (CPT 99453, 99454, 99457, 99458) code cohorts. We compared patient and encounter characteristics between both cohorts. Results: : We identified 27,756 encounters attributable to 11,326 patients who received RPM services for neurological disorders, of whom 5,785 (51.1%) received RPM via second-generation billing codes, 3,941 (34.8%) were female, 6,712 (59.3%) were between 45 and 64 years old, and 10,488 (92.6%) had a primary diagnosis of sleep–wake disorder. The second-generation cohort was significantly more likely to be female (41.5% vs. 27.8%, p < 0.001), be of age 65 or older (15.7% vs. 7.1%, p < 0.001), and reside in urban areas (93.4% vs. 87.6%, p < 0.001) than the first-generation cohort. Patients in the second-generation cohort were more likely to receive RPM in office settings (86.3% vs. 62.5%, p < 0.001), by physicians (77.0% vs. 40.3%, p < 0.001), and less likely for sleep–wake disorders (87.9% vs. 97.5%, p < 0.001) than the first-generation cohort. Patients who received RPM from physicians were most often evaluated by pulmonologists (31.4%). Discussion: : In this commercially insured patient population receiving RPM for neurological disorders, we found that sleep–wake disorders and non-neurologists were over-represented.